NONMEM Users Network Archive

Hosted by Cognigen

Pfizer postdoc position in cancer resistance modeling

From: Spilker, Mary <Mary.Spilker>
Date: Fri, 6 Nov 2020 16:41:15 +0000

Pfizer is recruiting a highly motivated postdoctoral candidate to develop and analyze mechanistic mathematical models that incorporate resistance mechanisms across patients and tumors, with the goal of improving predictions of therapeutic response for initial clinical trials. This Postdoctoral Fellowship is an opportunity to work within a dynamic Quantitative Systems Pharmacology group, who are at the forefront of the application of mechanistic systems models to address critical uncertainties in drug discovery and development.

The candidate will work within Pfizer Oncology<>, which is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide. Our strong pipeline includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.

In addition, Pfizer’s Postdoctoral Fellows pursue their research and career training in a culture steeped in the translation of basic science discovery into meaningful medicines for patients of all ages and geographies. Postdoctoral trainees are mentored in a setting that places a premium on your preparation for the next stage of your career whether it is a career in industry or academia.

The successful candidate will have earned a Ph.D. in Applied Mathematics, Engineering, Physics, Pharmaceutical Sciences, or other related discipline and has a demonstrated track record in scientific publication. The postdoctoral fellow will develop and analyze mathematical models of cancer resistance that integrate biological knowledge and available data from Pfizer’s preclinical and clinical programs, with the goal of providing tools for pre-clinical to clinical translation, dose selection, and clinical trial design. They will work collaboratively with biologists, clinicians, clinical pharmacologists, pharmacometricians, QSP and nonclinical modelers to improve designs for effective and durable oncology therapies.

For questions about this project or inquiries, please contact Mary Spilker (Mary.Spilker

To apply follow this link here<> (

Sunshine Act Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws
and implementing regulations. These laws and regulations require Pfizer to provide government agencies with information such
as a health care provider’s name, address and the type of payments or other value received, generally for public
disclosure. Subject to further legal review and statutory or regulatory clarification, which Pfizer intends to pursue,
reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal
transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs recruiting expenses
as a result of interviewing with Pfizer that we pay or reimburse, your name, address and the amount of payments made currently
will be reported to the government. If you have questions regarding this matter, please do not hesitate to contact your Talent
Acquisition representative.
EEO & Employment Eligibility Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without
regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or
veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment
as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and
IRCA. Pfizer is an E-Verify employer.
Received on Fri Nov 06 2020 - 11:41:15 EST

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to:

Once subscribed, you may contribute to the discussion by emailing: